DBMR - Pharmaceutical

Global Pruritus Drug Market - Industry Trends and Forecast to 2026

  • Pharmaceutical
  • Upcoming Report
  • Aug 2019
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Pruritus Drug Market By Types (Chronic Kidney Disease associated Pruritus, Chronic Liver Disease associated Pruritus, Atopic Dermatitis Associated Pruritus and Others), Drugs (Corticosteroids, Antihistamines, Counterirritants and Others), Route of Administration (Injectable, Topical, Oral), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retailers and Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast to 2026

Market Analysis: Global Pruritus Drug Market

Global pruritus drug market is growing at a substantial CAGR in the forecast period of 2019-2026. Increasing research and development expenses and high demand of novel therapies are some factors fueling the market growth

Market Definition: Global Pruritus Drug Market

Pruritus is referring to the severe itching associated with number of dermatological disorders including xerotic eczema, atopic dermatitis, and allergic contact dermatitis. It is typically an unpleasant sensation that elicits a desire to scratch vigorously and it is greatly altered by psychological and CNS factors.

According to the statistics published in U.S. Department of Health and Human Services, it was estimated approximately 10 to 25% people were affected with pruritus worldwide. Huge financial support from the government and increase in strategic alliances between the companies are key factors for market growth

Market Drivers

  • Increase prevalence of pruritus worldwide is driving the market growth
  • Increase special designation from the regulatory authorities is boosting the market growth
  • High specific demand of novel treatment is accelerating the market growth
  • Huge financial support to the researchers for developing novel intervention is enhancing the market growth

 Market Restraints

  • Effective treatment is eithers unavailable or unaffordable is restraining the market growth
  • Patent expiration of branded drugs and introduction of generic version is hindering the market growth
  • Lack of trained personnel and stringent safety regulations is hampering the market growth

Segmentation: Global Pruritus Drug Market

By Indication

  • Chronic Kidney Disease associated Pruritus
  • Chronic Liver Disease associated Pruritus
  • Atopic Dermatitis Associated Pruritus
  • Others

By Drugs

  • Corticosteroids
  • Antihistamines
  • Counterirritants
  • Others

By Routes of Administration

  • Injectable
  • Topical
  • Oral

By End Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retailers
  • Others

By Geography

  • North America

    • U.S.
    • Canada
    • Mexico

  • South America

    • Brazil
    • Rest of South America

  • Europe

    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Turkey
    • Belgium
    • Netherlands
    • Switzerland
    • Rest of Europe

  • Asia-Pacific

    • Japan
    • China
    • South Korea
    • India
    • Australia
    • Singapore
    • Thailand
    • Malaysia
    • Indonesia
    • Philippines
    • Rest of Asia Pacific

  • Middle East & Africa

    • South Africa
    • Rest of Middle East & Africa

Key Developments in the Market:

In August 2019, Cara Therapeutics in-licensed exclusive worldwide excluding South Korea and Japan to develop and commercialize oral Korsuva, selective inhibitor of kappa opioid receptors from Enteris BioPharma for the treatment of chronic pruritus. Under the deal terms, Enteris BioPharma granted Cara Therapeutics Peptelligence Technology to develop and commercialize Oral Korsuva in any indication. Enteris BioPharma will receive an upfront payment of USD 8.00 million comprised of USD 4.00 million in cash. Additionally, Enteris BioPharma is eligible to receive development, regulatory and tiered commercial milestone payments, as well as low, single-digit royalties based on net sales in the licensed territory granted by Enteris BioPharma.

In January 2019, Menlo Therapeutics received Breakthrough Therapy designation from the FDA for serlopitant, an oral NK1 receptor antagonist for the treatment of pruritus associated with Prurigo Nodularis (PN). The FDA’s Breakthrough Therapy designation expedites development and timeline process and facilitates FDA regular interaction and guidance which will make regulatory approval faster and hence help patients suffering from pruritus to regulatory approval faster.

Competitive Analysis:

Global pruritus drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global pruritus drug market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Players:

Few of the major competitors currently working in the global pruritus drug market are Cara Therapeutics, Enteris BioPharma, NeRRe Therapeutics, Menlo Therapeutics, XBiotech, Ipsen Pharma, Novus Therapeutics, Inc, AMOREPACIFIC CORPORATION, RDD Pharma, Ltd, Pfizer Inc and others.

Research Methodology: Global Pruritus Drug Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report

  • Current and future of global pruritus drug market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players


SKU-

Please fill in the below form for detailed Table of Content

Please fill in the below form for detailed List of Table

Please fill in the below form for detailed List of Figure

Please fill in the below form for detailed Inquire Before Buying

Choose License Type
  • $5400.00
  • $4200.00
BUY NOW ADD TO CART